000281871 001__ 281871
000281871 005__ 20251127142829.0
000281871 0247_ $$2doi$$a10.1055/a-2681-4558
000281871 0247_ $$2pmid$$apmid:41052542
000281871 0247_ $$2pmc$$apmc:PMC12591830
000281871 0247_ $$2ISSN$$a0720-4299
000281871 0247_ $$2ISSN$$a0015-8194
000281871 0247_ $$2ISSN$$a1439-3522
000281871 037__ $$aDZNE-2025-01242
000281871 041__ $$aGerman
000281871 082__ $$a150
000281871 1001_ $$00000-0001-5785-9594$$aHansen, Niels$$b0
000281871 245__ $$aKrankheitsmodifizierende Therapie mit Lecanemab bei früher Alzheimer-Demenz | Disease-modifying therapy with lecanemab for early Alzheimer's dementia
000281871 260__ $$aStuttgart [u.a.]$$bThieme$$c2025
000281871 3367_ $$2DRIVER$$aarticle
000281871 3367_ $$2DataCite$$aOutput Types/Journal article
000281871 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764249913_8034$$xReview Article
000281871 3367_ $$2BibTeX$$aARTICLE
000281871 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281871 3367_ $$00$$2EndNote$$aJournal Article
000281871 520__ $$aAlzheimer's disease (AD) is a severe and progressive neurodegenerative disease of the brain that has so far been treated with symptomatic drug and non-drug therapies as standard treatment. Following the approval of the monoclonal anti-amyloid antibody by the FDA, AD therapy has changed, as this therapy has made it possible to attenuate the biological disease process of AD. Lecanemab has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for approval in patients with early AD under two conditions. Firstly, homozygous ApoE4 carriers and secondly, patients receiving oral anticoagulants should not receive lecanemab. The following narrative review explains the mechanism of action, safety and side effects of lecanemab. Furthermore, risk factors for side effects are described. Finally, the first experiences with lecanemab are reported and the efficacy and financial aspects are discussed. Lecanemab leads to a temporary reduction in amyloid-ß deposits and to a benefit that can be reflected in everyday competence, cognition and quality of life and can be described as a breakthrough in AD's therapy due to its demonstrable biological and clinical efficacy.
000281871 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281871 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281871 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal, Humanized
000281871 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000281871 650_2 $$2MeSH$$aHumans
000281871 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000281871 650_2 $$2MeSH$$aAlzheimer Disease: psychology
000281871 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: therapeutic use
000281871 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: adverse effects
000281871 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000281871 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b1$$eLast author$$udzne
000281871 773__ $$0PERI:(DE-600)2037701-0$$a10.1055/a-2681-4558$$gVol. 93, no. 11, p. 453 - 460$$n11$$p453 - 460$$tFortschritte der Neurologie, Psychiatrie$$v93$$x0720-4299$$y2025
000281871 8564_ $$uhttps://pub.dzne.de/record/281871/files/DZNE-2025-01242.pdf$$yOpenAccess
000281871 8564_ $$uhttps://pub.dzne.de/record/281871/files/DZNE-2025-01242.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281871 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000281871 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281871 9141_ $$y2025
000281871 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000281871 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281871 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFORTSCHR NEUROL PSYC : 2022$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281871 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000281871 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-02$$wger
000281871 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000281871 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000281871 980__ $$ajournal
000281871 980__ $$aVDB
000281871 980__ $$aUNRESTRICTED
000281871 980__ $$aI:(DE-2719)1410006
000281871 9801_ $$aFullTexts